{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-005572","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.678261+00:00","generated_at":"2026-06-29T22:05:14.367002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Celldex reports Q2 2021 net loss of $13.4M; raises $287.5M in follow-on offering","bullets":["Net loss $13.4M ($0.34/share) vs $11.0M ($0.50/share) in Q2 2020; revenue $3.5M vs $0.2M.","Cash $164.0M at June 30, 2021; July follow-on offering added $287.5M gross ($270M net), extending runway through 2025.","CDX-0159 Phase 1b: 95% complete response in chronic inducible urticaria; 87% skin mast cell depletion with single dose.","Plan to initiate CDX-0159 study in prurigo nodularis in Q4 2021 and subcutaneous formulation Phase 1 in Q3 2021.","CDX-1140 expansion cohorts recruiting; CDX-527 dose escalation completed, expansion cohorts planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-005572","json":"https://secwatch.observer/filing/0001171843-21-005572.json","markdown":"https://secwatch.observer/filing/0001171843-21-005572.md","text":"https://secwatch.observer/filing/0001171843-21-005572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184321005572/0001171843-21-005572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184321005572/f8k_080521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:05:14.367002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}